Yahoo Finance Live anchors discuss reports that Apple has ditched plans to increase iPhone 14 production.
Yahoo Finance Live anchors discuss Biogen stock performance on promising Alzheimer’s drug trial data.
Novavax, Inc. stock is trending on the Yahoo Finance Platform. Here is a visualization of $NVAX performance over time, how that performance compares to the wider industry, and analyst projections for the current quarter.Check out the ticker page here.
The benchmark S&P 500, which is typically viewed as the best barometer of stock market health, produced its worst first-half return in 52 years. As for the growth-driven Nasdaq Composite, an index largely responsible for pushing the stock market to new highs, it's lost about a third of its value. This puts both the S&P 500 and Nasdaq firmly in a bear market.
In this article, we discuss 11 best dividend aristocrat stocks to buy heading into recession. If you want to see more stocks in this selection, click 5 Best Dividend Aristocrat Stocks To Buy Heading Into Recession. Several of the world’s biggest economies face increasing recession risks as a result of the skyrocketing inflation and the […]
Creating reliable streams of retirement income is one of the most important elements of a person's financial plan. A retirement industry giant says it now has a new way for retirees to meet this vital challenge. Fidelity Investments plans to … Continue reading → The post There's a New Way to Convert Your 401(k) into a Pension-like Stream of Income appeared first on SmartAsset Blog.
The Dow Jones Industrial Average rose Wednesday, ahead of Fed chief Powell's speech, struggling to avoid a seventh straight decline.
Biogen stock rips higher on a promising new drug. Here's what Wall Street is saying.
Analysts are either optimistic or delusional. But either way, they see a big S&P 500 29% rally coming — and have picked favorite stocks.
Mind Medicine (MindMed) Inc. ("MindMed") (NASDAQ: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the pricing of its underwritten public offering of 7,058,823 common shares, together with accompanying warrants to purchase 7,058,823 common shares. The combined offering price to the public of each common share and accompanying warrant is $4.25. Each common share will be sold in combination with an accompanying
Biogen stock exploded higher Wednesday — bringing shares of other Alzheimer's plays with it — after its experimental treatment succeeded in a test.
The CBOE Volatility Index has skyrocketed 89% so far this year. Morningstar put together a list of stocks with one- and three-year betas of 0.8 or lower. Then it screened for stocks that are undervalued, according to Morningstar analysts' fair value estimates.
For many retail investors, the events of late January 2021 will go down in legend. The year 2020 could be characterized as the rise of the retail investor. Amid the retail revolution, one voice rose to the top.
In this analysis, we will look at some of the aspects the market may have adapted when pricing Tesla, Inc. (NASDAQ:TSLA) and explore why the stock may retain current levels. Even though the fundamentals may not reflect the current valuation.
BENGALURU (Reuters) -The Federal Reserve will hike its key interest rate to a much higher peak than predicted two weeks ago and the risks are skewed towards an even higher terminal rate, according to economists polled by Reuters. That change in expectations came after the Fed raised rates by 75 basis points last week for the third straight meeting and foresaw going higher than it had previously thought to tame inflation, which is running over four times above target. Since then, already battered global stocks went much deeper into bear market territory - a decline of 20% or more - on fears of recession and most currencies weakened further against the multi-decade high dollar.
Anyone following stock market trends in 2022 will be well aware of the widespread drawbacks; apart from some outliers such as energy, most corners of the market have been beaten to a pulp. The main culprits are easily identified by now; a combination of a slowing economy, rampant inflation, rates hikes to halt it, and Russia’s invasion of Ukraine and the global implications are all responsible factors. Stock market giants have not been immune either and many have seen huge chunks of their valuat
In this article, we will discuss the 10 dividend paying stocks to buy according to Morgan Stanley’s quant screen. If you want to explore similar stocks, you can also take a look at 5 Best Dividend Stocks to Buy According to Morgan Stanley’s Quant Screen. Morgan Stanley’s Base Case: S&P Falling to $3,400 by Year […]
Investors on Wall Street continued to have doubts about when the stock market is likely to recover, as ongoing worries about inflation, interest rates, and the global financial system have everyone on edge. Biotech stocks have been among those hit hardest by the bear market in 2022, but Biogen (NASDAQ: BIIB) announced good news in a key clinical trial that has huge implications for those suffering from a harsh and debilitating disease. Biogen's favorable outcome also gave industry peer Eli Lilly (NYSE: LLY) a boost, on optimism that a new way of coming up with important treatments could spur further successes.
At last check, 26 of the 30 Dow stocks have lost ground this year, with many falling much more than the index. One of the few stocks that have survived this year's sell-off in the Dow Jones might catch some investors by surprise. After delivering rather lackluster performance in recent years, oil giant Chevron (NYSE: CVX) is leading the Dow Jones this year with a more than 20% gain.
(Bloomberg) -- Apple Inc. is backing off plans to increase production of its new iPhones this year after an anticipated surge in demand failed to materialize, according to people familiar with the matter.Most Read from BloombergApple Ditches iPhone Production Increase After Demand FaltersGermany Suspects Sabotage Hit Russia’s Nord Stream PipelinesAlzheimer’s Progression Slowed by Drug in Major TrialPutin’s Mobilization Hits Russia’s Economy in Its Weak SpotsRussia Declares Victory in Sham Ukrain